A recent randomized, double-blind, placebo-controlled study published in the International Journal of Physical Medicine and Rehabilitationevaluated the combination in 85 healthy men and women over the course of two weeks. MOVE3 significantly reduced levels of CTX-II, a biomarker of cartilage degradation, versus placebo after one and two weeks of exercise—by 12.9% and 17.7%, respectively. MOVE3 also relieved joint pain immediately after exercise, 12 hours after exercise, and one week, and stiffness 12 hours after exercise.
Related: Bone & Joint Support for Every Generation Boomers and Millennials: Conquering the Great Divide Study Confirms Efficacy of Stratum’s NEM for Joint Health"The body of science supporting exercise and recovery benefits for both Omega-3 and NEM continues to grow, but this study is unique because it demonstrates benefits in healthy people consuming the MOVE3 formulation afterthey have exercised," said Adam Ismail, Chief Strategy Officer of the KD Pharma Group in the press release. "For sports nutrition products, it is important that consumers be able to feel the benefit, and the fact that we saw a significant improvement compared to placebo means the subjects not only felt the impact of MOVE3 but observed the effects in a rapid timeframe."
"Conducting this clinical trial in exercising healthy adults will allow brands to make label claims relating to joint pain and stiffness and even cartilage protection," added Kevin Ruff, Ph.D., MBA, Senior Director of Scientific & Regulatory Affairs for Stratum Nutrition. "This is an additional benefit that MOVE3 provides beyond any other combination product on the market."